Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors

Medical Oncology

Volumn 24, Issue 4, 2007, Pages 372-378

  Rubenstein, Marvin ^a,b   Tsui, Paulus ^a   Guinan, Patrick ^a,b,c  

^a Hektoen Institute for Medical Research   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Antisense; Prostate cancer; Therapy

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; CANCER GROWTH FACTOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR; MESSENGER RNA; PACLITAXEL; PROTEIN BCL 2;

ARTICLE; AUTOCRINE EFFECT; BINDING SITE; CELL STRAIN LNCAP; DRUG EFFICACY; HUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; TUMOR CELL;

ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BINDING SITES; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOPHOSPHAMIDE; HUMANS; MALE; OLIGONUCLEOTIDES, ANTISENSE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 36249025698     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-007-0023-y     Document Type: Article

References (18)

1. Rubenstein M, Tsui P, Guinan P. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors. Med Hypotheses 2005;65:905-7.
2. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides with multiple binding sites for the treatment of prostate tumors and their applicability to combination therapy. Methods Find Exp Clin Pharmacol 2006;28:1-4.
3. Rubenstein M, Tsui P, Guinan P. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors. (In Press Med Oncol 2007:24).
4. Rubenstein M, Anderson KM, Tsui P, Guinan P. Synthesis of branched antisense oligonucleotides having multiple specificities: treatment of hormone insensitive prostate cancer. Med Hypotheses 2006;67:1374-79.
5. Rubenstein M, Mirochnik Y, Chou P, Guinan P. Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol 1996;62:194-200.
6. Yamanaka K, Miyake H, Zangemeister-wittke U, Jansen B, Gleave M. Novel bispecific antisense oligonucleotides inhibiting both Bcl-2 and Bcl-xL expression induce apoptosis and enhance chemosensitivity in human androgen-independent prostate cancer cells. Proc Am Assoc Cancer Res 2004;45:Abstract #2930.
7. Lee BS, Fujita M, Khazenzon NM, Wachsmann-Hogiu S, Farkas DL, Black KL, Ljubimova JY, Holler E. Synthesis of polymeric prodrug Polycefin based on biodegradable poly (malic acid) for drug delivery. Proc Am Assoc Cancer Res 2006;97:258a.
8. Rubenstein M, Tsui P, Guinan P. A review of antisense oligonucleotides in the treatment of human disease. Drugs of the Future 2004;29:893-909.
9. http://www.afhu.org/site/press_releases/news_lego.htm
10. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J. Progression to androgen independence is delayed by adjuvant treatment with antisense bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res 1999;5:2891-98.
11. Rubenstein M, Slobodskoy L, Mirochnik Y, Guinan P. Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and Taxol. Med Oncol 2003;20:29-35.
12. Tsui P, Rubenstein M, Guinan P. Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model. Med Oncol 2004;21:339-48.
13. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and transformation by a specific deoxynucleotide. Proc Natl Acad Sci USA 1979;75:280-4.
14. Mirochnik Y, Rubenstein M, Guinan P. Two constructed antibody derived delivery vehicles for targeting oligodeoxynucleotides to prostate tumors expressing prostate specific antigen. Drug Del 2004;11:161-7.
15. Castelli J, Wood KA, Youle RJ. The 2-5A system in viral infection and apoptosis. Biomed Pharmacother 1998;52:386-90.
16. Kondo S, Kondo Y, Li G, Silverman RH, Cowell JK. Targeted therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA. Oncogene 1998;16:3323-30.
17. Ying SY, Lin S. High-performance subtractive hybridization of cDNSs by covalent bonding between complementary nucleotides. Biotechniques 1999;26:966-79.
18. Ying SY, Chuong CM, Lin S. Suppression of activin-induced apoptosis by novel antisense strategy in human prostate cancer cells. Biochem Biophys Res Commun 1999;265:669-73.